Show summary Hide summary
At a Washington gathering this spring, a 23-year-old Vanderbilt student publicly described a profound loss of sexual feeling and emotional connection after using antidepressants — a testimony that has reignited debate over the risks and benefits of a drug class prescribed to millions. With antidepressant use among young people climbing sharply in recent years, the issue now matters for patients, prescribers and policy makers alike.
At the MAHA Institute event in early May, the student, Laura Friedman, told the audience she experienced near-total numbness in her genitals and an inability to feel close to family after stopping a selective serotonin reuptake inhibitor. Her account stood out in a program focused on what the organizers described as the “overmedicalization” of mental health.
For many patients, however, the calculus is different: clinicians say **SSRIs** can be life-saving for depression, obsessive-compulsive disorder and anxiety. Still, Friedman’s case and similar reports have drawn attention to a poorly understood condition known as **post‑SSRI sexual dysfunction**, or **PSSD**, and raised questions about how common and how serious it might be.
Five Eyes: China planting bogus job listings to recruit and spy on foreign staff
Sexual dysfunction: 23-year-old goes public to break the silence
What clinicians are seeing
Physicians who treat sexual and urological disorders describe a range of symptoms linked to PSSD. Patients report diminished genital sensation, problems achieving or maintaining erections, delayed or absent orgasm and, in some cases, a broader emotional blunting. Some also describe changes in bladder or bowel function.
Dr. Kenneth Peters of Corewell Health says the puzzling feature of PSSD is timing: symptoms sometimes persist or even emerge after the medication is stopped, contrary to the expectation that side effects should resolve when a drug is discontinued. Dr. Irwin Goldstein of San Diego Sexual Medicine adds that his research suggests there may be measurable physiological changes — including nerve or tissue alterations — in some patients.
- Symptoms: genital numbness, erectile or orgasmic difficulties, reduced libido, emotional detachment
- Onset: can begin while taking an SSRI or after stopping it
- Recognition: the European Medicines Agency acknowledged PSSD in 2019; the U.S. has not established formal diagnostic criteria
- Course: variable — some recover within months or years, others report long-term symptoms
- Treatment: currently no standardized, proven therapies; many patients seek anecdotal remedies online
How common is PSSD?
Estimating incidence is difficult. Roughly one in six Americans takes an **SSRI**, but experts say only a small fraction of those users report persistent sexual dysfunction severe enough to be classified as PSSD. Published estimates range widely; clinicians cite figures that could be under 1% or several percent, but confirmatory large-scale studies are lacking.
Peters points to surveys showing many patients with PSSD seek help but often feel dismissed by clinicians, underscoring gaps in recognition and diagnostic training. He and other researchers say more systematic data collection is essential to clarify risk levels and identify who may be most vulnerable.
Treatment prospects and research gaps
There is no agreed-upon cure. Some patients recover spontaneously over time; others explore hormonal therapies, electrical stimulation or off‑label medications with mixed or anecdotal results. Online communities and forums often serve as the primary information source for sufferers, which clinicians say can be helpful for peer support but also risks spreading unverified remedies.
Research into mechanisms and treatments has been limited and largely driven by patient advocacy. Peters is seeking to expand studies with grant proposals to the National Institutes of Health, but he warns that funding shortfalls have slowed progress.
Policy and public debate
The PSSD conversation has intersected with a broader policy debate about psychiatric medication. After Robert F. Kennedy Jr. became Health and Human Services secretary, the administration launched reviews of pediatric prescribing of several psychiatric drugs. A subsequent executive order that criticized an “over‑reliance” on medication alarmed patients and clinicians who say access to SSRIs can be lifesaving.
Advocates for greater caution say prescribers should discuss rare but potentially serious sexual side effects as part of informed consent. Others emphasize that restricting access would risk harming people who benefit from these medications.
Practical takeaways for patients
Experts suggest several pragmatic steps for anyone considering or taking an SSRI:
- Discuss potential sexual and emotional side effects with your prescriber before starting treatment.
- If symptoms arise, report them promptly; do not assume they will automatically disappear when the drug is stopped.
- Ask about alternatives and adjuncts — therapy, lifestyle changes and non‑SSRI medications — and weigh benefits against risks.
- Seek clinicians experienced in sexual medicine if symptoms persist; peer support groups may help but verify medical guidance through trusted sources.
Clinicians interviewed for this report emphasized a balanced message: **SSRIs** remain an important tool in treating serious mental illness, but awareness of possible long‑term sexual and emotional side effects should inform treatment decisions and follow‑up. Better research, clearer diagnostic criteria and open clinician‑patient conversations are the immediate priorities if the medical community is to address both the benefits and the harms.
